Men with castration-sensitive prostate cancer and bone metastases whose androgen-deprivation therapy was initiated within @ months of study entry were randomly assigned in a blinded @:@ ratio to receive zoledronic acid ( @ mg intravenously every @ weeks ) or a placebo .